Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
41.84 ^USD	-1.44%		+2.52%	-17.30%

Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	MT

Ionis Pharmaceuticals to present at upcoming investor conferences

August 31, 2022 at 07:54 am EDT

CARLSBAD - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022

Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022

Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022

A live webcast and additional information about each fireside chat can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. Replays will be available on the Ionis website within 48 hours of each event.

About Ionis Pharmaceuticals, Inc.

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.

Contact:

Tel: 760-603-2331

Latest news about Ionis Pharmaceuticals, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	Apr. 10	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating	Apr. 09	MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 03:00 PM	Apr. 08
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	Apr. 08
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	Apr. 07	CI
Transcript : Ionis Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:30 AM	Mar. 20
Sector Update: Health Care Stocks Gain Premarket Wednesday	Mar. 13	MT
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up	Mar. 13	MT
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	Mar. 13	RE
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	Mar. 13	CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating	Mar. 06	MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM	Mar. 05
Ionis Pharmaceuticals, Inc. Announces Executive Changes	Feb. 29	CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	Feb. 26	MT
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Transcript : Ionis Pharmaceuticals, Inc., 2023 Earnings Call, Feb 21, 2024	Feb. 21
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	Feb. 21	MT
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	Feb. 21	MT
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q4 Revenue $325M	Feb. 21	MT
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 21	CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2023	Feb. 21	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ

Chart Ionis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.84 USD

Average target price

58.13 USD

Spread / Average Target

+38.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IONIS PHARMACEUTICALS, INC.	-17.30%	6.19B
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research